Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Atea Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOSTON, NOV. 19, 2025 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (ATEA OR COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ENGAGED IN THE DISCOVERY AND DEVELOPMENT OF ORAL ANTIVIRAL THERAPEUTICS FOR SERIOUS VIRAL DISEASES, TODAY ANNOUNCED THAT JEAN-PIERRE SOMMADOSSI, PHD, CHIEF EXECUTIVE OFFICER AND FOUNDER OF ATEA, TOGETHER WITH OTHER MEMBERS OF THE ATEA MANAGEMENT TEAM, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE ON WEDNESDAY, DECEMBER 3, 2025 AT 10:00 A.M. ET IN CORAL GABLES, FL.

ATEA PHARMACEUTICALS TO PRESENT AT THE 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE

PATIENT ENROLLMENT ON TRACK IN GLOBAL PHASE 3 PROGRAM FOR TREATMENT OF HEPATITIS C VIRUS (HCV), TOPLINE RESULTS FROM NORTH AMERICA TRIAL EXPECTED MID-2026 NEW DATA SHOW BEMNIFOSBUVIR HAS UNIQUE DUAL MECHANISM AGAINST HCV NEW DATA PRESENTED AT THE LIVER MEETING  , THE ANNUAL MEETING OF AASLD, SUPPORT BEMNIFOSBUVIR/RUZASVIR AS A POTENTIAL BEST-IN-CLASS THERAPY FOR THE TREATMENT OF HCV COMPANY ANNOUNCES NEW HEPATITIS E VIRUS (HEV) DEVELOPMENT PROGRAM COMPANY HOLDING CONFERENCE CALL TODAY AT 4:30 PM ET COMPANY HOSTING HCV KOL EVENT NOVEMBER 13 TH AT 10 AM ET BOSTON, NOV. 12, 2025 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (ATEA OR COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ENGAGED IN THE DISCOVERY AND DEVELOPMENT OF ORAL ANTIVIRAL THERAPEUTICS FOR SERIOUS VIRAL DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, ANNOUNCED NEW RESEARCH FINDINGS, INCLUDING EVIDENCE OF A UNIQUE DUAL MECHANISM OF ACTION FOR BEMNIFOSBUVIR AGAINST HEPATITIS C VIRUS (HCV) AND THE EXPANSION OF THE COMPANY'S ANTIVIRAL PIPELINE WITH A NEW HEPATITIS E VIRUS (HEV) PROGRAM, AND PROVIDED A BUSINESS UPDATE. THE COMPANY'S COMBINATION REGIMEN OF BEMNIFOSBUVIR, A NUCLEOTIDE ANALOG HCV NS5B POLYMERASE INHIBITOR, AND RUZASVIR, AN NS5A INHIBITOR, FOR THE TREATMENT OF HCV IS CURRENTLY BEING EVALUATED IN A GLOBAL PHASE 3 DEVELOPMENT PROGRAM.

ATEA PHARMACEUTICALS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

COMPANY HOSTING VIRTUAL KOL PANEL EVENT THURSDAY, NOVEMBER 13TH AT 10:00 AM ET COMPANY HOSTING VIRTUAL KOL PANEL EVENT THURSDAY, NOVEMBER 13TH AT 10:00 AM ET

ATEA PHARMACEUTICALS PRESENTS NEW DATA SUPPORTING THE FIXED-DOSE COMBINATION OF BEMNIFOSBUVIR AND RUZASVIR AS A POTENTIAL BEST-IN-CLASS REGIMEN FOR TREATMENT OF HEPATITIS C VIRUS INFECTION AT THE LIVER MEETING 2025

BOSTON, NOV. 05, 2025 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (ATEA OR COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ENGAGED IN THE DISCOVERY AND DEVELOPMENT OF ORAL ANTIVIRAL THERAPEUTICS FOR SERIOUS VIRAL DISEASES, TODAY ANNOUNCED THAT IT WILL HOST A LIVE CONFERENCE CALL AND AUDIO WEBCAST ON WEDNESDAY, NOVEMBER 12, 2025, AT 4:30 P.M. ET TO REPORT FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND TO PROVIDE A BUSINESS UPDATE.

ATEA PHARMACEUTICALS TO HOST THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE CONFERENCE CALL ON NOVEMBER 12, 2025

BOSTON, OCT. 22, 2025 (GLOBE NEWSWIRE) -- ATEA PHARMACEUTICALS, INC. (NASDAQ: AVIR) (ATEA OR COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ENGAGED IN THE DISCOVERY AND DEVELOPMENT OF ORAL ANTIVIRAL THERAPEUTICS FOR SERIOUS VIRAL DISEASES, TODAY ANNOUNCED THAT IT WILL HOST A VIRTUAL KEY OPINION LEADER (KOL) EVENT ON THURSDAY, NOVEMBER 13, 2025 AT 10:00 AM ET TO DISCUSS A WIDE RANGE OF HEPATITIS C VIRUS (HCV)-RELATED TOPICS INCLUDING THE CURRENT HCV PATIENT POPULATION, THE IMPORTANCE OF EARLY DIAGNOSIS AND TREATMENT, PUBLIC POLICY INITIATIVES INCLUDING THE TEST-AND-TREAT MODEL OF CARE, WHETHER HCV ERADICATION IN NORTH AMERICA IS AN ACHIEVABLE GOAL, AND WHAT A NEW OPTIMIZED HCV THERAPY COULD PROVIDE FOR PRESCRIBERS AND PATIENTS. TO REGISTER,CLICK HERE.

Atea Pharmaceuticals, Inc.

AVIR

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Atea Pharmaceuticals, Inc.

AVIR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AVIR